AU Patent

AU2021202500A1 — Tablet formulation of 2-fluoro-N-methyl-4-(7-(quinolin-6- ylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)Benzamide

Assigned to Novartis AG · Expires 2021-05-20 · 5y expired

What this patent protects

The present invention is related to tablets comprising of 2-fluoro-N-methyl-4-[7 (quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, processes for the production thereof, and uses in the treatment of certain cancers.

USPTO Abstract

The present invention is related to tablets comprising of 2-fluoro-N-methyl-4-[7 (quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, processes for the production thereof, and uses in the treatment of certain cancers.

Drugs covered by this patent

Patent Metadata

Patent number
AU2021202500A1
Jurisdiction
AU
Classification
—
Expires
2021-05-20
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.